HIV-1 Virologic Rebound Due to Coadministration of Divalent Cations and Bictegravir

摘要

A potential drug-drug interaction exists between divalent and trivalent cations (Ca2 , Fe3 , Mg2 , Al3 , Zn2 ) and HIV-1 integrase strand transfer inhibitors (INSTIs). There are limited case reports describing the clinical significance of this potential interaction and none to our knowledge identifying zinc co-administration with INSTIs. In this report we present a patient taking bictegravir/emtricitabine/tenofovir alafenamide who became viremic after ingesting zinc and calcium supplements and later was able to obtain virologic re-suppression after discontinuing supplements. This case represents a potential significant drug interaction between a commonly prescribed antiretroviral drug class and readily available over-the-counter divalent cation products.